Valuation: Alpha Cognition Inc.

Market Cap 249M 178M 159M 146M 133M 16.88B 255M 1.74B 695M 8.94B 669M 655M 28.25B P/E 2026 *
-6.43x
P/E 2027 * -12x
Enterprise Value 249M 178M 159M 146M 133M 16.88B 255M 1.74B 695M 8.94B 669M 655M 28.25B EV / Sales 2026 *
6.95x
EV / Sales 2027 * 3.74x
Free-Float
94.87%
Yield 2026 *
-
Yield 2027 * -
1 day+4.02%
1 week-4.26%
Current month-2.40%
1 month-6.26%
3 months+1.19%
6 months+43.36%
Current year+31.23%
1 week 8.17
Extreme 8.17
9.35
1 month 7.98
Extreme 7.9768
9.36
Current year 4.5
Extreme 4.5
10.14
1 year 4.5
Extreme 4.5
10.14
3 years 3.75
Extreme 3.75
18.5
5 years 3.5
Extreme 3.5025
27
10 years 3.5
Extreme 3.5025
45
Manager TitleAgeSince
Chief Executive Officer 58 2021-04-11
Chief Tech/Sci/R&D Officer - 2021-03-21
Director of Finance/CFO 48 2024-10-20
Director TitleAgeSince
Director/Board Member 41 2021-03-17
Director/Board Member 66 2021-03-21
Director/Board Member 58 2021-04-11
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26
Opaleye Management, Inc.
BuyCompany 19,050 0.0875%
9/25/26
Opaleye Management, Inc.
BuyCompany 13,426 0.0616%
9/16/26
Opaleye Management, Inc.
BuyCompany 80,170 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
+4.02%-4.26%+49.65%+24.80% 179M
+0.61%+10.62%+58.16%+149.73% 1,255B
+3.81%+2.82%+48.35%+82.58% 641B
+3.09%+2.95%+39.10%+108.48% 505B
+1.25%-0.78%+52.56%+66.87% 381B
+3.93%+6.02%+82.28%+45.44% 357B
+2.10%+4.26%+34.93%+61.10% 303B
+1.92%+9.37%+13.43%+36.55% 286B
+3.73%+6.82%+61.48%+77.31% 249B
+4.19%+9.68%+42.96%+113.85% 208B
Average +2.08%+1.86%+48.29%+76.67% 418.54B
Weighted average by Cap. +1.36%+3.90%+50.61%+97.79%

Financials

2026 *2027 *
Net sales 35.87M 25.65M 22.87M 20.95M 19.07M 2.43B 36.67M 250M 100M 1.29B 96.31M 94.25M 4.06B 66.62M 47.63M 42.47M 38.91M 35.42M 4.51B 68.1M 464M 186M 2.39B 179M 175M 7.55B
Net income -40.64M -29.06M -25.91M -23.73M -21.6M -2.75B -41.54M -283M -113M -1.46B -109M -107M -4.6B -20.19M -14.44M -12.87M -11.79M -10.73M -1.37B -20.64M -141M -56.31M -724M -54.21M -53.05M -2.29B
Net Debt - -
Projected Income Statement - Annual - Alpha Cognition Inc.
Logo Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Employees
-
Date Price Change Volume
26-11-04 US$8.530 +4.02% 169,037
26-11-03 US$8.200 -1.68% 108,033
26-11-02 US$8.340 -4.58% 57,339
26-10-30 US$8.740 -4.90% 48,323
26-10-29 US$9.190 +0.22% 62,917
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Alpha Cognition Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.530USD
Average target price
18.00USD
Spread / Average Target
+111.02%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alpha Cognition Inc.
  1. Stock Market
  2. Stocks
  3. ACOG Stock